The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > COMMENTARY
COMMENTARY
- Approval of Switch-OTC Epadel Puts Spotlight on Quality, Track Record of Pharmacists
November 9, 2012
- Final Preparations Underway for Trial Run of Medical Database
September 25, 2012
- Competition Getting Fiercer in COPD Drug Market
September 13, 2012
- FY2013 Budget Expected to Have Positive Impact on Pharmaceutical and Medical Device Industries
August 30, 2012
- Pharmaceutical Bar Coding Initiatives Spreading Among Western Countries
August 21, 2012
- Government Shows Consideration towards Municipalities on IPV Price Issue
August 14, 2012
- Challenges Emerging from Hiroshima: Improvement of Wholesalers' “Services of Convenience”
August 1, 2012
- Integration of Advanced Healthcare System to Strengthen Linkage Between Development, Insurance, and Regulatory Approval
July 10, 2012
- Major Generic Drug Makers Trying New Strategies to Boost Product Strengths
July 6, 2012
- Gov’t to Support Development of Innovative Drugs of Japanese Origin through Drug Discovery Support Network
June 22, 2012
- Discussions on Long-Listed Drugs Must Balance Interests of All Stakeholders
June 14, 2012
- Supply of New Drugs Prior to NHI Price Listing to Increase as More Makers Target Drugs with Unmet Medical Needs
April 20, 2012
- Fewer Takers, High Pass Rate in Nat’l Pharmacists’ Exam for 1st Graduates of Six-year Education System
April 5, 2012
- Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 2
March 26, 2012
- Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 1
March 19, 2012
- Indications for Boosted Alliances, Acquisitions in Vaccine Business among Major Japanese Companies
March 13, 2012
- Further Provisions Required – One Year since the Great East Japan Earthquake
March 12, 2012
- Major US, European Drug Makers Report Growth in 2011 as Patent Cliff Approaches
March 5, 2012
- Will Wholesalers Be Able to Succeed at Reform This Time?
February 20, 2012
- Industry Should Prepare Arguments in Advance to Ward Off Possibility of 3 Consecutive NHI Price Revisions
January 23, 2012
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…